A recent study suggests that individuals who come off new GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight far faster than those who stop conventional diet and exercise plans.
Findings released in a prominent medical journal points out that while overweight people often shed a large proportion of their total mass while on the medication, the mass comes back at an estimated rate of 0.8 kg per month once they quit.
"Users using such treatments should be cognizant of the potential of fast weight regain when the therapy ends," warns researcher Dr. Susan Jebb.
That rate of recovery suggests a reversion to original mass within about a year and a half.
Analyzing Approaches
The analysis, which examined 37 of studies involving thousands of patients, compared the results of these new drugs with conventional dieting.
Researchers note that people who shed pounds through diet and exercise generally have a more gradual creep back—around 0.1 kg a month—post-intervention.
Explaining the Fast Regain
Nutrition scientists believe the mode of action of the injections is key to understanding the amplified rebound.
These medications imitate a natural hormone called glucagon-like peptide-1, which moderates feelings of fullness.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the body to produce less of its endogenous GLP-1, and may also reduce responsiveness to its actions," said Dr. Adam Collins, a dietetics specialist.
"Stopping of this hormone supplement results in hunger is uncontrolled, making overeating far more likely."
A Lifelong Condition?
Medical guidelines suggest the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
A number of clinicians contend that, considering the significant potential of relapse, the treatment should be considered long-term.
This perspective is supported by drug manufacturers, who state that the results "emphasize the chronic character of obesity," comparing it to managing diseases like hypertension.
Patient Experiences
Users who have discontinued the jabs explain a powerful return of hunger.
"It was like something that goes on and you become extremely hungry," said one woman.
The struggle is exacerbated if users have not established lasting dietary or behavioural modifications during treatment.
Widespread Interest
Figures show that millions of people in the UK have used these injections in the last 12 months, with interest remaining high.
- Adoption is more common among women compared to males.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private prescriptions rather than the NHS.
Finally, researchers stress that while the jabs are powerful tools for shedding pounds, they are not a standalone fix and lasting health benefits relies on ongoing behavioural support.
